Drug Profile
Research programme: monoclonal antibodies and small molecule therapeutics - MediaPharma
Alternative Names: mab EV20; MP BF 001; MP-1959 (SP-2); MP-3546; MP-AA-1; MP-E-8-3/1959; MP-E-8.3; MP-EV-20; MP-EV20-DC54; MP-EV20-RT; MP-HE-001A; MP-HE-001B; MP-HE-001C; MP-PN-1; MP-PN-2; MP-RM-1 (ErbB-3 antibody)Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator MediaPharma
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
- Mechanism of Action Carrier protein inhibitors; CD248 antigen inhibitors; Epidermal growth factor receptor modulators; ERBB-3 receptor antagonists; Hypoxia-inducible factor 1 inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; Receptor protein-tyrosine kinase modulators; Transcriptional elongation factor inhibitors; Transcriptional elongation factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Diabetic foot ulcer; Pancreatic cancer; Phaeochromocytoma; Renal cell carcinoma; Stroke; Von Hippel-Lindau disease
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer in Italy
- 28 Oct 2020 No recent reports of development identified for preclinical development in Phaeochromocytoma in Italy
- 28 Oct 2020 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in Italy